29
Views
19
CrossRef citations to date
0
Altmetric
Original Article

Lansoprazole versus Omeprazole in Active Duodenal Ulcer a Double-Blind, Randomized, Comparative Study

, , , , &
Pages 210-215 | Received 18 Feb 1994, Accepted 20 Jun 1994, Published online: 08 Jul 2009
 

Abstract

Background: Lansoprazole is a new substituted benzimidazole that inhibits the H+, K+-adenosine triphosphatase in the parietal cell and, like the first developed proton pump inhibitor omeprazole, gives a strong inhibition of gastric acid output. Methods: In this double-blind randomized comparative study patients with active duodenal ulcers were treated with either 30 mg lansoprazole or 20 mg omeprazole in the morning. AH demographic data in the two treatment groups were comparable. Results: A total of 279 patients entered the study. There was no difference in healing rates between the groups either after 2 weeks (86.2% for lansoprazole and 82.1% for omeprazole) or after 4 weeks (97.1% and 96.2%). No patient ceased treatment owing to side effects. Conclusions: Both lansoprazole and omeprazole generate very high healing rates and good symptom relief in active duodenal ulcer. Side effects are few and mild.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.